MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms.

Machine translation Machine translation
类别 Systematic review
期刊The pharmacogenomics journal
Year 2013
連結 Pubmed, DOI
两个关键变量映射协会MTHFR基因（C677T（rs1801133）和A1298C（rs1801131））与响应甲氨蝶呤（MTX）仍然是有争议的。我们调查这些和其他标记跨越基因作为MTX疗效和在英国的类风湿关节炎（RA）患者队列不良事件的预测因子，并用所有公布的数据进行了荟萃分析的两个关键变种。该标记单核苷酸多态性（SNPs）进行基因分型的309例明确定义的结果对MTX治疗和17项研究被纳入荟萃分析。与MTX疗效或毒性在我们的英国的队列中检测到测试的单核苷酸多态性无关联。与以往的研究通过meta分析结合我们的数据后，随机效应合并比值比（OR）为C677T和A1298C均与疗效或毒性没有关联无论是单核苷酸多态性（功效：OR = 1.05（95％可信区间（ CI）0.83-1.32）和OR = 0.81（95％CI为0.53-1.24），分别毒性：OR = 1.38（95％CI为0.90-2.12）和OR = 1.19（95％CI为0.80-1.78），分别）。现有的证据表明，MTHFR基因C677T和A1298C基因多态性不响应MTX治疗的RA患者的可靠预测指标。
This translation has been produced by an automated software. If you wish to submit your own translation, please send it to translations@epistemonikos.org
Epistemonikos ID: 1175480a209e83422b0bdcd5ceb0eac8feba13c8
First added on: Sep 17, 2013
Warning
This is a machine translation from an article in Epistemonikos.

Machine translations cannot be considered reliable in order to make health decisions.

See an official translation in the following languages: English

If you prefer to see the machine translation we assume you accept our terms of use